Posts

Immune protection against tuberculosis reinfection driv...

The body’s first line of defense against tuberculosis (TB) involves immune cells...

Interdisciplinary Rice graduate program earns $3 millio...

HOUSTON – (Aug. 29, 2024) – A research traineeship program developed by a team o...

Biotech executive and serial entrepreneur appointed to ...

The Wake Forest Institute for Regenerative Medicine (WFIRM) proudly announces th...

Silicon chip propels 6G communications forward

Terahertz communications represent the next frontier in wireless technology, pro...

RISE project awarded NIH grant

Xiaopeng Zhao, a professor in the Department of Mechanical, Aerospace, and Biome...

Texas A&M teams up to advance robotic dexterity

Texas A&M University is joining a new National Science Foundation (NSF) Engineer...

Northwestern receives $55 million to advance health res...

CHICAGO — The Northwestern University Clinical and Translational Sciences (NUCAT...

Several advantages when medical abortion is started at ...

Being at home is as safe as at the hospital when a medical abortion after twelve...

HeterMM: Applying in-DRAM index to heterogeneous memory...

Emerging byte-addressable storage technologies, such as NVM, provide a more cost...

A distinct “repair” role of regulatory T cells in fract...

The study uncovers a unique reparative function of regulatory T cells (Tregs) in...

Consensus paper: Carcinogenicity of gene therapies

Researchers from the University of Pennsylvania, Perelman School of Medicine, Ge...

Drought risk and awareness gaps in global society

Natural disasters have threatened to human beings and the ecosystem. Among the v...

Promising antibiotic candidates discovered in microbes ...

Antibiotics are the linchpin of modern medicine: without them, anyone with open ...

Bavarian Nordic Receives Mpox Vaccine Green Light From ...

Bavarian Nordic announced today that its vaccine, JYNNEOS, has been licensed by ...

McKesson Invests $2.5B to Acquire Majority Stake in Flo...

McKesson has planned to enhance its oncology platform with a significant investm...

EC upgrades approval for J&J’s Rybrevant/chemotherapy c...

Rybrevant has been granted a Type II approval extension to treat NSCLC with EGFR...